PEPG vs. LXRX, RVNC, ANL, TRDA, BMEA, NKTX, HROW, ORGO, HRTX, and AMRN
Should you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Lexicon Pharmaceuticals (LXRX), Revance Therapeutics (RVNC), Adlai Nortye (ANL), Entrada Therapeutics (TRDA), Biomea Fusion (BMEA), Nkarta (NKTX), Harrow Health (HROW), Organogenesis (ORGO), Heron Therapeutics (HRTX), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Lexicon Pharmaceuticals (NASDAQ:LXRX) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends.
Lexicon Pharmaceuticals received 451 more outperform votes than PepGen when rated by MarketBeat users. However, 85.71% of users gave PepGen an outperform vote while only 64.66% of users gave Lexicon Pharmaceuticals an outperform vote.
PepGen has lower revenue, but higher earnings than Lexicon Pharmaceuticals. PepGen is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Lexicon Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.
Lexicon Pharmaceuticals presently has a consensus target price of $5.00, suggesting a potential upside of 193.26%. PepGen has a consensus target price of $24.67, suggesting a potential upside of 116.56%. Given PepGen's higher probable upside, research analysts clearly believe Lexicon Pharmaceuticals is more favorable than PepGen.
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 4.5% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
PepGen has a net margin of 0.00% compared to PepGen's net margin of -14,573.20%. Lexicon Pharmaceuticals' return on equity of -57.56% beat PepGen's return on equity.
In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than PepGen. MarketBeat recorded 3 mentions for Lexicon Pharmaceuticals and 1 mentions for PepGen. PepGen's average media sentiment score of 0.33 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.
Summary
Lexicon Pharmaceuticals beats PepGen on 9 of the 17 factors compared between the two stocks.
Get PepGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
